CN118416069A - 用卡博特韦和利匹韦林治疗hiv的方法 - Google Patents

用卡博特韦和利匹韦林治疗hiv的方法 Download PDF

Info

Publication number
CN118416069A
CN118416069A CN202410349180.8A CN202410349180A CN118416069A CN 118416069 A CN118416069 A CN 118416069A CN 202410349180 A CN202410349180 A CN 202410349180A CN 118416069 A CN118416069 A CN 118416069A
Authority
CN
China
Prior art keywords
salt
rilpivirine
cabotegravir
once
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410349180.8A
Other languages
English (en)
Chinese (zh)
Inventor
H·M·L·格劳韦尔斯
S·L·福德
D·A·马戈利斯
S·L·F·罗塞努
W·R·斯普林
R·M·范索林根-里斯泰亚
P·E·O·威廉姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
ViiV Healthcare Co
Original Assignee
Janssen Sciences Ireland ULC
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC, ViiV Healthcare Co filed Critical Janssen Sciences Ireland ULC
Publication of CN118416069A publication Critical patent/CN118416069A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202410349180.8A 2019-10-01 2020-10-01 用卡博特韦和利匹韦林治疗hiv的方法 Pending CN118416069A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962908995P 2019-10-01 2019-10-01
US201962908882P 2019-10-01 2019-10-01
US62/908,882 2019-10-01
US62/908,995 2019-10-01
US202063037782P 2020-06-11 2020-06-11
US63/037,782 2020-06-11
US202063052214P 2020-07-15 2020-07-15
US63/052,214 2020-07-15
CN202080069721.1A CN114502166A (zh) 2019-10-01 2020-10-01 用卡博特韦和利匹韦林治疗hiv的方法
PCT/IB2020/059185 WO2021064618A1 (en) 2019-10-01 2020-10-01 Method for treating hiv with cabotegravir and rilpivirine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080069721.1A Division CN114502166A (zh) 2019-10-01 2020-10-01 用卡博特韦和利匹韦林治疗hiv的方法

Publications (1)

Publication Number Publication Date
CN118416069A true CN118416069A (zh) 2024-08-02

Family

ID=72826936

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410349180.8A Pending CN118416069A (zh) 2019-10-01 2020-10-01 用卡博特韦和利匹韦林治疗hiv的方法
CN202080069721.1A Pending CN114502166A (zh) 2019-10-01 2020-10-01 用卡博特韦和利匹韦林治疗hiv的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080069721.1A Pending CN114502166A (zh) 2019-10-01 2020-10-01 用卡博特韦和利匹韦林治疗hiv的方法

Country Status (11)

Country Link
US (3) US20220347174A1 (https=)
EP (1) EP4037661A1 (https=)
JP (1) JP7791083B2 (https=)
KR (1) KR20220074880A (https=)
CN (2) CN118416069A (https=)
AU (1) AU2020358156B2 (https=)
CA (1) CA3155587A1 (https=)
CL (1) CL2022000790A1 (https=)
IL (1) IL290716A (https=)
MX (1) MX2022003945A (https=)
WO (1) WO2021064618A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
WO2023222755A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
WO2023222754A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Rilpivirine for use in the treatment or prevention of hiv infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010299959B2 (en) * 2009-09-22 2016-07-21 Tibotec Pharmaceuticals Treatment and prevention of HIV infection
US11564921B2 (en) * 2017-07-21 2023-01-31 Viiv Healthcare Company Regimens for treating HIV infections and AIDS
CN109568328A (zh) * 2017-09-29 2019-04-05 重庆药友制药有限责任公司 一种用于预防和治疗hiv感染的药物组合物
BR112021025655A2 (pt) * 2019-06-19 2022-02-01 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana

Also Published As

Publication number Publication date
US20220347174A1 (en) 2022-11-03
CA3155587A1 (en) 2021-04-08
JP2022550828A (ja) 2022-12-05
WO2021064618A1 (en) 2021-04-08
CN114502166A (zh) 2022-05-13
MX2022003945A (es) 2022-04-25
AU2020358156B2 (en) 2024-06-06
US20250302829A1 (en) 2025-10-02
AU2020358156A1 (en) 2022-04-21
US20250302830A1 (en) 2025-10-02
IL290716A (en) 2022-04-01
EP4037661A1 (en) 2022-08-10
CL2022000790A1 (es) 2022-11-25
JP7791083B2 (ja) 2025-12-23
KR20220074880A (ko) 2022-06-03

Similar Documents

Publication Publication Date Title
Deeks Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection: ED Deeks
US20250302829A1 (en) Method for treating hiv with cabotegravir and rilpivirine
US20200113917A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
JP2025111701A (ja) 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
CN111032158A (zh) 用于治疗抑郁的nk-1拮抗剂组合物和方法
Rivera et al. HIV pre-exposure prophylaxis: new and upcoming drugs to address the HIV epidemic
Yu et al. Pharmacokinetic drug-drug interactions involving antiretroviral agents: an update
JP7287906B2 (ja) 組み合わせ並びにその使用及びそれによる治療
Dirajlal-Fargo et al. Pediatric antiretroviral therapy
RU2840867C1 (ru) Способ лечения вич каботегравиром и рилпивирином
Koren et al. Scientific basis of antiretroviral therapy
US20240091159A1 (en) Combination and Uses and Treatments Thereof
US20220096487A1 (en) Methods for treating hiv with dolutegravir and lamivudine
Spagnuolo et al. Lenacapavir for the Treatment of Heavily Treatment-experienced People with Multi-class Resistant HIV.
Pandit et al. PRINCIPLES AND SCIENTIFIC BASIS OF HIV THERAPY
Ballon New drugs
Vanangamudi et al. Current and Promising Multiclass Drug Regimens and Long-Acting Formulation Drugs in HIV Therapy
Flamm Highlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting
Tablets FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE
Injection Full prescribing information
ULC et al. Pr Mylan-Efavirenz
Blonk et al. and David M. Burger
Francisco Data Released from Startmrk Study of Isentress Versus Efavirenz

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination